Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing

Founded by pioneers of CRISPR biology

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell therapies are critical now and for the future of cancer therapy and that advanced genome editing is necessary to develop sophisticated cell therapies to treat a variety of malignancies. We are developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for a range of tumor types.

about lab image

Leadership Team

Executive Leadership Team

Rachel Haurwitz photo

Rachel Haurwitz, Ph.D.

President and Chief Executive Officer

Steven Kanner photo

Steve Kanner, Ph.D.

Chief Scientific Officer

Ruhi Khan photo

Ruhi Khan

Chief Business Officer

Barbara McClung photo

Barbara McClung, J.D.

Chief Legal Officer and Corporate Secretary

Jason O’Byrne photo

Jason O’Byrne

Chief Financial Officer

Syed Rizvi photo

Syed Rizvi, M.D.

Chief Medical Officer

Senior Leadership Team

Elaine Alambra photo

Elaine Alambra

Vice President of Regulatory Affairs and Quality Assurance

Zili An photo

Zili An, M.D.

Vice President of Pharmacology

Amy Figueroa photo

Amy Figueroa, CFA

Vice President of Investor Relations and Corporate Communications

Ryan Fischesser photo

Ryan Fischesser

Vice President of Finance and Controller

Scott Gradia photo

Scott Gradia, Ph.D.

Vice President of Platform Research

Cindy Hayashi photo

Cindy Hayashi

Vice President of Human Resources

tonia nesheiwat photo

Tonia Nesheiwat, Pharm.D.

Vice President of Medical Affairs

daniel poon photo

Daniel Poon

Vice President of Operations and Information Technology

socorro portella photo

Socorro Portella, M.D.

Vice President of Clinical Development

Justin Skoble photo

Justin Skoble, Ph.D.

Vice President of Technical Operations

Saeid Yazdani photo

Saeid Yazdani

Vice President of Portfolio Management

Board of Directors

Scientific Advisory Board


We are committed to fostering strong partnerships to develop and advance genome-edited therapies. If you are interested in partnering with Caribou, please contact our team.

abbvie logo
leukemia & lymphoma society logo


Caribou has an extensive CRISPR technology IP portfolio, including an exclusive license from The Regents of the University of California and the University of Vienna to the foundational CRISPR-Cas9 IP invented by Jennifer Doudna, Emmanuelle Charpentier, and their colleagues. Caribou licenses this CRISPR-Cas9 IP and certain of its own Cas9 IP to other companies for use in multiple market sectors including but not limited to research tools, transgenic research animals, internal research, diagnostics, and industrial biotechnology. For information regarding licensing, click here.

Caribou has entered into licenses with recognized leaders in many market sectors. Such licenses include:

Corteva Agriscience logo
Danisco US Inc. logo
Genus plc logo
Helmholtz Zentrum München logo
Integrated DNA Technologies, Inc. logo
Intellia Therapeutics, Inc. logo
The Jackson Laboratory logo
Medical Research Council logo
Novartis logo
Novome Biotechnologies, Inc. logo
Oxford Nanopore Technologies Ltd logo
regional fish logo
RenOVAte Biosciences logo
Takara logo
tree co logo